CRISPR/Cas9-mediated knockout of six glycosyltransferase genes in Nicotiana benthamiana for the production of recombinant proteins lacking β-1,2-xyllose and core α-1,3-fucose

Julia Jansing1, Markus Sack1, Sruthy Maria Augustine1, Rainer Fischer1,a,b and Luisa Bortesi1,b,*

1Department for Molecular Biotechnology, RWTH Aachen University, Aachen, Germany

Summary

Plants offer fast, flexible and easily scalable alternative platforms for the production of pharmaceutical proteins, but differences between plant and mammalian N-linked glycans, including the presence of β-1,2-xyllose and core α-1,3-fucose residues in plants, can affect the activity, potency and immunogenicity of plant-derived proteins. Nicotiana benthamiana is widely used for the transient expression of recombinant proteins so it is desirable to modify the endogenous N-glycosylation machinery to allow the synthesis of complex N-glycans lacking β-1,2-xyllose and core α-1,3-fucose. Here, we used multiplex CRISPR/Cas9 genome editing to generate N. benthamiana production lines deficient in plant-specific α-1,3-fucosyltransferase and β-1,2-xylosyltransferase activity, reflecting the mutation of six different genes. We confirmed the functional gene knockouts by Sanger sequencing and mass spectrometry-based N-glycan analysis of endogenous proteins and the recombinant monoclonal antibody 2G12. Furthermore, we compared the CD64-binding affinity of 2G12 glycovariants produced in wild-type N. benthamiana, the newly generated PX-KO line, and Chinese hamster ovary (CHO) cells, confirming that the glyco-engineered antibody performed as well as its CHO-produced counterpart.

Introduction

Plants have been used for the production of recombinant proteins for almost 30 years (Hiatt et al., 1989) and several technical, veterinary and pharmaceutical plant-made proteins are now commercially available (Sack et al., 2015). In addition to versatility and speed, one of the main strengths of plant-based production platforms is their ability to carry out complex post-translational modifications, particularly the addition of complex N-glycans related to the structures found on native mammalian proteins (Schähs et al., 2007). However, there are various differences between plant and mammalian N-glycans, e.g. plant N-glycans lack sialic acid and core α-1,6-fucose residues, but β-1,2-xyllose and core α-1,3-fucose are present (Lerouge et al., 1998). The potential immunogenicity of the plant-specific N-glycans has been discussed extensively in the context of molecular farming (Bardor et al., 2003; Botto et al., 2010; Schmid et al. and Tekoah, 2016), and although there are no conclusive data questioning the safety of plant-made pharmaceuticals (Botto et al., 2010; Rup et al., 2017; Santos et al., 2016; Tekoah et al., 2015; Ward et al., 2014), their elimination is desirable to produce glycoproteins lacking non-human epitopes.

N-glycosylation affects many properties of recombinant glycoproteins produced in planta. For example, plant-made antibodies for passive immunization are as efficient as their mammalian counterparts in virus neutralization assays, but have a shorter half-life in the blood due to a higher clearance rate (Ko et al., 2003). Removal of the core fucose residue—be it the mammalian α-1,6-fucose or the plant α-1,3-fucose—from the N-glycan of an antibody led to a 20–50-fold increase in antibody-dependent cellular cytotoxicity (Cox et al., 2006; Loos et al., 2015; Shields et al., 2002; Zeitlin et al., 2011). Furthermore, the first plant-made pharmaceutical protein to be approved by the FDA for human parenteral administration (taliglucerase alfa, proprietary name Elelyso, produced by Protalix Biotherapeutics as a replacement therapy of Gaucher’s disease) benefits from terminal mannose residues on the α-1,3-fucose- and β-1,2-xyllose-containing N-glycan structures generated in plant cell vacuoles (Tekoah et al., 2013). Exposed mannose residues are required for the efficient uptake of the enzyme into macrophages but terminal sialic acid residues are added when the equivalent product is made in mammalian cells, and these residues must be trimmed off in vitro before formulation (Grabowski et al., 2014; Mor, 2015). These examples demonstrate the ambiguity of N-glycosylation in plant-made pharmaceutical proteins: in some cases, the plant N-glycans are beneficial and in other cases they are detrimental.

Fortunately, we can modify the genomes of plants used for recombinant protein production in order to tweak their N-glycosylation machinery (Loos and Steinkellner, 2014). The first report describing the elimination of β-1,2-xyllose and α-1,3-fucose from N-glycans in the model plant Arabidopsis thaliana made use of the random T-DNA insertion mutant collection (Alonso et al., 2003) to identify lines mutated in the single β-1,2-xylosyltransferase (XylT) and two α-1,3-fucosyltransferase (FucT) genes, verify their inactivation, and then cross them to generate triple knockout A. thaliana lines. The resulting lines were viable and had a normal phenotype despite their inability to transfer β-1,2-xyllose and α-1,3-fucose to their N-glycans.
(Strasser et al., 2004). Such comprehensive mutant collections do not exist for any other plant species used for recombinant protein production, so more direct methods are required. In the moss Physcomitrella patens, targeted integration of the human β-1,4-galactosyltransferase gene was used to knock out the FucT and XylT genes in order to humanize the N-glycosylation machinery (Huether et al., 2005). This approach relies on homologous recombination, which is highly efficient in moss, but much less so in higher plants. Consequently, in the common duckweed (Lemma minor) (Cox et al., 2006), alfalfa (Medicago sativa) (Sourrouille et al., 2008) and the tobacco-like species Nicotiana benthamiana (Strasser et al., 2008), an RNAi-mediated knockdown approach was used to reduce plant-specific glycosyltransferase activities. The N. benthamiana ΔXT/FT RNAi line developed almost 10 years ago (Strasser et al., 2008) has been a popular production variety for pharmaceutical proteins (Castilho et al., 2011; Dent et al., 2016; Olinger et al., 2012), even though this and other RNAi lines still have the capacity to synthesize α-1,3-fucose and β-1,2-xylose, albeit to a lesser extent than their wild-type counterparts. Random mutagenesis by exposure to ethylmethanesulfonate (EMS) was used to develop N. benthamiana lines with point mutations in two XylT and five FucT genes, but 19%–34% of N-glycans on endogenous leaf proteins in the 5KO (FucT) and 7KO (FucT + XylT) lines still contained α-1,3-fucose. By super-transforming the 7KO lines with a FucT RNAi construct, the relative level of N-glycans containing core α-1,3-fucose was reduced to 0.6%–0.9%, but α-1,3-fucosyltransferase activity was not fully eliminated (Wetereings and Van Eldik, 2013).

With the advent of designer nucleases such as zinc finger nucleases (ZFNs) (Kim et al., 1996), transcription activator-like effector nucleases (TALENs) (Christian et al., 2018), and most recently CRISPR-related nucleases like Cas9 (Jinek et al., 2012) and Cpf1 (Zetsche et al., 2015), it has become increasingly straightforward to knock out the functions of multiple genes. In N. benthamiana, the two XylT genes and two of the five FucT genes were knocked out with TALENs to completely eliminate the β-1,2-xylosyltransferase activity and reduce core α-1,3-fucosyltransferase activity by 60%, the latter confirming that the other FucT genes would need to be targeted to eliminate FucT activity completely (Li et al., 2016). Two recent publications describe the successful multiplex CRISPR-mediated knockout of four or five FucT genes and two XylT genes in Nicotiana tabacum BY-2 suspension cells (Hanania et al., 2017; Mercx et al., 2017), resulting in the absence of α-1,3-fucose and β-1,2-xylose in endogenous and recombinant proteins, and no differences in cell morphology or growth between the knockout and wild-type lines. However, to the best of our knowledge, the comprehensive knockout of all active XylT and FucT genes in intact N. benthamiana plants has not been achieved thus far. Here, we report the highly efficient multiplex knockout of two XylT and four FucT genes in N. benthamiana using CRISPR/Cas9 to generate lines for the production of recombinant proteins completely devoid of core α-1,3-fucose and/or β-1,2-xylose residues.

Results

Identification of α-1,3-fucosyltransferase and β-1,2-xylosyltransferase target genes

Two N. benthamiana β-1,2-xylosyltransferase (XylT) genes and five α-1,3-fucosyltransferase (FucT) genes with two alleles each were identified by literature research (Li et al., 2016; Strasser et al., 2008; Weterings and Van Eldik, 2013) and were used as BLAST queries against the draft N. benthamiana genome sequence (Bombarely et al., 2012) from the Sol Genomics Network (https://solgenomics.net; (Fernandez-Pozo et al., 2015) and the Queensland University of Technology (http://benthtome.qut.edu.au; (Naim et al., 2012). Based on the sequences identified in the draft genome, specific primer pairs (Table S1) were designed for exon 1 (XylT) or exons 1, 2 and 4 (FucT) and were used to amplify and re-sequence the regions of interest from N. benthamiana genome DNA. The resulting sequences matched the published sequences with accession numbers Niben101Scf04551 (XylT 1), Niben101Scf04205 (XylT 2), Niben101Scf01272 (FucT 1), Niben101Scf02631 (FucT 2), Niben101Scf05494 (FucT 3), Niben101Scf17626 (FucT 4) and Niben101Scf05447 (FucT 5). The intron borders were found to be conserved in FucT 1, 2, 3 and 4 (Figure 1a), but not the intronless gene FucT 5, which also contains a Y288D amino acid substitution in the highly conserved fucosyltransferase motif. A mutation of that particular Tyrosine residue of a human FucT VI has been shown to completely inactivate the enzyme (Jost et al., 2005). FucT 5 also lacks a TATA box, indicating it is likely to be an inactive pseudogene (Weterings and Van Eldik, 2013). Accordingly, FucT 5 was not included in our knockout strategy.

Design, evaluation and selection of gRNAs

The exon sequences were aligned to identify regions of homology that could be targeted by the same guide RNAs (gRNAs). Candidate gRNAs were evaluated for potential off-targets, and six gRNAs each were designed to target the first and second exon of XylT 1 + 2 and FucT 1 + 2 but no other coding sequences in the genome. The gRNAs were transiently co-expressed with Cas9 in N. benthamiana leaves, the genomic DNA was extracted after 5 days, the targeted regions amplified using gene-specific primers (Table S2), and the mutation frequencies determined by next-generation sequencing (Appendix S1, Table S3). We found that 0%–6% of the analysed amplicons were mutated at the anticipated target site, and the three most efficient gRNAs for both XylT 1 + 2 and FucT 1 + 2 were selected to be used in the knockout constructs for stable transformation (Figure 1b). At a later time, the publication by Li et al. (2016), showing that knocking out FucT 1 + 2 by TALENs does not completely abolish FucT activity, brought the genes FucT 3, 4 and 5 to our attention. FucT 3, 4 and 5 cluster together and have low nucleotide sequence identity with FucT 1 and 2, but the genes share the conserved catalytic fucosyltransferase motif in exon 4 (Jost et al., 2005). A single gRNA (F7) targeting this motif in the FucT 1–4 genes was therefore identified (a “silver bullet”), and included in the knockout constructs without testing its activity (Figure 1a, b). This gRNA was a perfect match for the target in FucT 1 and 2 but had a PAM-distal G → C mismatch in FucT 3 and 4 (Figure 2b) which should be tolerated by Cas9 but might reduce the Cas9 nuclease activity in these two genes.

Design and cloning of the multiplex knockout constructs for plant transformation

Three constructs for the generation of stable transgenic plants were prepared (Figure 1b): F-KO (targeting four FucT genes), X-KO (targeting two XylT genes) and FX-KO (targeting four FucT genes and two XylT genes). Using synthetic polycistronic tRNA-gRNA (PTG) cassettes (Xie et al., 2015), 3–7 gRNAs were included in each of the three constructs to facilitate the multiplex knockout of up to six genes. The cas9 cassette was located upstream of the

© 2018 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 17, 350–361

CRISPRRed tobacco lacking plant-specific glycans 351
Figure 1  FucT 1-4 and XylT 1 + 2 gene structure, schematic of transformation constructs and gRNA properties. (a) Structure of the four FucT genes targeted by four gRNAs and the two XylT genes targeted by three gRNAs (http://wormweb.org/exonintron). The FucT genes have seven exons, and conserved intron borders. FucT 2 has a premature stop codon in exon 7 resulting in a loss of 41 amino acids from the translated protein. FucT 4 has an unusually long intron 1 of ~7.8 kb. Three gRNAs (indicated by blue arrows) targeted exon 2 of FucT 1 and 2 (blue box), and one gRNA (green arrow) targeted the conserved catalytic motif in exon 4 of FucT 1, 2, 3 and 4 (green box). The three XylT-specific gRNAs target exon 1 of XylT 1 and 2 (orange box). Altogether, the coloured boxes indicate the eight exons targeted by the selected gRNAs, resulting in a total of 16 targeted exons when both alleles of the six genes are considered. (b) The knockout constructs were flanked by left and right T-DNA borders (LB and RB). To facilitate the removal of the construct from the plant genome, loxP sites (blue triangles) and human gRNA target sequences (red arrows) were included. For the selection of transformed plants on kanamycin, we included a neomycin phosphotransferase gene (nptII). The plant-codon-optimized cas9 gene was controlled by a hybrid 35SPPDK promoter, and the corresponding polycistronic tRNA/gRNA gene (PTG) was controlled by the A. thaliana U6 promoter. The three genes were separated by scaffold attachment regions (SARs). In the three constructs F-KO, X-KO and FX-KO, four, three and seven gRNAs are expressed from the PTG, respectively, and the gRNA sequences are provided including the PAM in bold. Not drawn to scale. (c) Properties of the gRNAs, their target genes and exons, the number of genomic targets, and their mutation efficiencies (Eff.) in T0 plants.

The gRNA cassette and was separated from it by a scaffold attachment region (SAR). Next to the left and right borders (LB and RB), highly active human gRNA target sequences with no potential off-target sites in the N. benthamiana genome, as well as loxP sites, were included to make the constructs excisable with either Cas9 or Cre recombinase in case segregating the transgene(s) from the final lines was not possible. After construct validation by restriction digest and Sanger sequencing, the knockout constructs were used to transform Agrobacterium tumefaciens.

Generation, screening and selection of genome-edited plants

T0 generation

In two rounds of transformation, 57 X-KO plants, 43 F-KO plants and 74 FX-KO plants were regenerated and screened for mutations in the target genes by the Sanger sequencing of PCR amplicons. Gene-specific primer pairs were used to separately amplify homologous target sequences, e.g. from XylT 1 and 2. A high percentage of plants (80%, 83% and 73%) showed evidence for Cas9-mediated editing in at least one of the 4, 12 or 16 targeted exons respectively (Figure 1a, c). The mutations identified by sequencing mostly consisted of +1 insertions or short deletions, but some larger deletions of up to 371 bp were also found. Almost half of the mutated plants had mosaic mutation patterns in one or more of the target genes. The efficiencies of the FucT- and XylT-specific gRNAs varied (Figure 1c): the three gRNAs targeting XylT 1 and 2 caused mutations in 62%–67% of the plants, whereas only 10%–14% of plants were mutated in exon 2 of FucT 1 and 2 targeted by three previously tested gRNAs. Unexpectedly, the ‘silver bullet’ gRNA F7 targeting the conserved fucosyltransferase motif in exon 4 of FucT 1-4 achieved different
CRISPRRed tobacco lacking plant-specific glycans 353

Figure 2  Sequencing and Western blot analysis for the T2 lines X-KO #34-4-4 and F-KO #6-10-6 and the F2 line FX-KO #20-4. (a) Mutations in XylT 1 and 2 of X-KO #34-4-4 as identified by Sanger sequencing of PCR amplicons (XylT 1) and TOPO-cloned PCR products (XylT 2). The corresponding wild-type sequence is shown above, the gRNA target sequences are indicated by coloured boxes, and the PAM sequences are shown in bold. (b) Mutations in FucT 1, 2, 3 and 4 of F-KO #6-10-6. The PAM-distal mismatch between the gRNA and FucT 3 and 4 is highlighted in yellow. (c) Mutations in FucT 1-4 and XylT 1 and 2 of FX-KO #20-4. Five of six genes carry homozygous mutations, with the exception of FucT 3 which has biallelic mutations. (d) Western blot of FX-KO #20-4 in comparison to N. benthamiana wild type, F-KO #6-10-6 and X-KO #34-4-4. ~10 μg of total soluble protein were loaded for each sample. Anti-fucose blot: 1st antibody rabbit-anti-a1,3-fucose (1 : 10 000), 2nd antibody goat-anti-rabbit H+L AP-labelled (1 : 10 000, pre-absorbed). Anti-xylose blot: 1st antibody rabbit-anti-b1,2-xylose (1 : 5000), 2nd antibody goat-anti-rabbit H+L AP-labelled (1 : 10 000, pre-absorbed).
were selected, as well as six plants with at least monoallelic mutations in the four targeted FucT genes from the F-KO construct (Table S4). The selected lines were allowed to self-pollinate and produce seeds.

**T₂ generation**

Depending on the number of mutated genes and the zygosity of the mutations in the T₂ line, 10–15 plants per line were grown for each of the 16 selected X-KO and F-KO genotypes. To quickly pre-screen the resulting 185 plants for the inheritance and zygosity of the mutations detected in the T₁ generation, high-resolution melt analysis (HRMA) was carried out with gene-specific primer pairs (Table S5) and lines with putative biallelic or homozygous mutations in all targeted genes were selected. This subgroup of plants was further tested by dot blot analysis with α-1,3-fucose-specific and β-1,2-xylene-specific antibodies (Figure S1a, b). Lines in which the dot blot signal intensity was lower than the wild-type signal (or absent) were then genotyped by Sanger sequencing. We identified eight X-KO lines with no evidence of XytT activity in the dot blots (Figure S1a, blue circles) and with complex biallelic or homozygous mutations in both XytT genes. Because the gene-specific PCR amplicons covering two alleles were sequenced together, the resulting overlapping sequencing traces were difficult to analyse. The complexity and size of the mutations in both alleles made it difficult to specify the nature of the mutations in some cases, but we could determine that there was no wild-type allele present without resorting to TOPO-cloning. We also selected four F-KO lines with mutations in six or seven of the eight FucT alleles in the T₁ generation, only five plants per line were grown in the T₂ generation. They were characterized by the Sanger sequencing of purified amplicons or TOPO-cloned PCR products if necessary (Figure 2a), as well as dot blots (Figure S1c).

**T₃ generation**

The four selected F-KO lines still had monoallelic mutations in one or two of the four targeted FucT genes in the T₁ generation. Therefore, 50 plants for each line were grown in the T₂ generation to ensure a good chance of identifying plants with homozygous mutations in all four target genes. The resulting 200 plants were pre-screened by Sanger sequencing of FucT 2 exon 4, which had been heterozygous in all tested T₁ plants. We identified 15–16 plants per line with homozygous mutations in FucT 2, and these were tested by dot blot using wild-type and T₁ samples as controls (Figure S1d). Surprisingly, there was no substantial further reduction in signal intensity compared to the T₁ sample of each parental line, even though the T₁ plant was not mutated in all the target alleles. Because the signal intensities were similar, six plants per line were selected randomly and genotyped by Sanger sequencing. Line F-KO #6-10-6 with homozygous mutations in all four targeted FucT genes (Figure 2b, Figure S1d, blue circle) was selected for N-glycan analysis.

### Analysis of total protein N-glycans in selected F-KO and X-KO lines

Leaf material from the mature T₂ plants F-KO #6-10-6 and X-KO #34-4-4 was treated with PNGase A to release the N-glycans followed by MALDI-TOF mass spectrometry analysis of the free glycan structures (Table 2, Figure S2a, b). N-glycans were identified by their characteristic masses. The F-KO sample comprised ~20% high-mannose glycans and ~80% complex glycans, but no core-fucosylated N-glycans were detected (Figure S2a). A trace amount of Gn(FA)X was detected (the Lewis² epitope with α-1,4-fucose), which would not be affected by knocking out α-1,3-fucosyltransferase. A similar picture emerged for the X-KO sample, which comprised ~28% high-mannose glycans, ~70% complex type glycans without xylose, and trace amounts of Gn(FA) and Gn(FA)F with the aforementioned Lewis² epitope (Figure S2b). These results confirmed the complete knockout of all active FucT genes in the F-KO line, and all active XytT genes in the X-KO line.

| Generation | Line     | Gene | FucT 1 | FucT 2 | FucT 3 | FucT 4 | XytT 1 | XytT 2 |
|------------|----------|------|--------|--------|--------|--------|--------|--------|
| **T₁**     | F-KO #6-3| Mutation | +1/+1  | +1     | +1     | +1/–6  |        |        |
|            | Zygoity  | Homo  | Het    | Het    | Bial   |        |        |        |
|            | F-KO #6-10 | Mutation | –1/–6  | –1     | +1     | +1/1   |        |        |
|            | Zygoity  | Homo  | Het    | Het    | Homo   |        |        |        |
|            | F-KO #35-8 | Mutation | –371/–371 | –1     | +1/1   | +1/1   |        |        |
|            | Zygoity  | Bial  | Het    | Het    | Homo   |        |        |        |
|            | F-KO #35-11 | Mutation | –371/–371 | –1     | +1/1   | +1/1   |        |        |
|            | Zygoity  | Homo  | Het    | Homo   | Homo   |        |        |        |
| **T₂**     | F-KO #6-10-6 | Mutation | –1/–1  | –1/–1  | +1/1   | +1/1   |        |        |
|            | Zygoity  | Homo  | Homo   | Homo   | Homo   |        |        |        |
|            | X-KO #34-4-4 | Mutation | –74/–74  | Homo  |        |        | –83/–59 |        |
|            | Zygoity  | Homo  | Homo   | Homo   | Homo   |        |        |        |
|            | FX-KO #20-4 | Mutation | –74/–74  | Homo  |        |        | –6/–59  | –6/–59 |
|            | Zygoity  | Homo  | Homo   | Homo   | Homo   |        |        |        |

The generation, type and name of line and the mutation status of the two, four or six target genes are provided. The length of the mutation is indicated, as well as the type (deletion –, insertion +). Biallelic and homozygous mutations are shown in the format mut/mut. Numbers in parentheses (mut,mut) indicate multiple mutations in one allele, i.e. mutations induced at different gRNA target sites. The full knockout lines confirmed by N-glycan analysis are printed in bold.

© 2018 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 17, 350–361
Transient expression and glycan analysis of the antibody 2G12 in selected T₂ plants

To confirm that the selected knockout lines were suitable for the production of recombinant proteins lacking plant-specific glycans, the antibody 2G12 (Trkola et al., 1996) was transiently expressed in young, detached leaves of lines F-KO #6-10-6 and X-KO #34-4-4, and wild-type N. benthamiana plants, followed by purification and analysis for the identification and quantification of the heavy chain glycopeptides (Table 3). As expected, the results confirmed that no core α-1,3-fucose or β-1,2-xylose were present in the different N-glycan structures commonly found on plant proteins. Consequently, the predominant glycoform shifted from GnGnX to GnGn in wild-type leaves (62%) to GnGnX (67% in the F-KO lines) or GnGn (50% in the X-KO lines). The absence of α-1,3-fucose or β-1,2-xylose indicated the successful functional knockout of all active gene variants in each of the lines.

F₁ generation of FX-KO

The confirmed knockout lines F-KO #6-10-6 and X-KO #34-4-4 were crossed to generate a heterozygous FX-KO line. Because N. benthamiana is a self-pollinating plant with delicate flowers, manual crossing is a challenging procedure. To ensure that the progeny of the F-KO #6-10-6 × X-KO #34-4-4 cross were indeed hybrids and not self-pollination products, 20 plants were tested by dot blot with the β-1,2-xylose-specific and α-1,3-fucose-specific antibodies. The plants were expected to have heterozygous mutations in the six XylT and FucT genes and thus show reactivity in both dot blots. To our surprise, we identified FX-KO #20, a line that tested negative in both dot blots (Figure S3a). Sanger sequencing of PCR amplicons showed that one mutated allele per gene was inherited from the parental lines and that new mutations had been induced in the wild-type allele of all six genes (Figure S3b). Antibody 2G12 was transiently expressed in the detached leaves of line FX-KO #20, and the N-glycans of the purified antibody heavy chain were analysed as above (Figure S3c). No β-1,2-xylosylated N-glycans were found, but 11% of the heavy chain glycopeptides contained α-1,3-fucose. N-glycan analysis of the leaf proteome showed that ~50% of N-glycans contained α-1,3-fucose, and that no β-1,2-xylose was present within the limit of detection (Figure S3d, e). This confirmed the complete knockout of the two XylT genes already in the F₁ generation, and a substantial reduction in the level of α-1,3-fucosylation in comparison to wild-type N. benthamiana. The remaining α-1,3-fucosyltransferase activity indicated that some of the newly induced mutations must have been somatic rather than germinal. To investigate the heritability of the mutations, the plant was allowed to self-pollinate and the next generation was analysed.

F₂ generation of candidate line FX-KO #20

Thirty F₂ plants were grown from seeds obtained from the self-pollination of line FX-KO #20 and tested by dot blot analysis with the β-1,2-xylose-specific and α-1,3-fucose-specific antibodies. None of the extracts were recognized by the xylose-specific antibody, and 10 were also not recognized by the fucose-specific

### Table 2 MALDI-TOF-MS analysis of total endogenous leaf protein N-glycans released from lines F-KO #6-10-6, X-KO #34-4-4 and FX-KO #20-4.

| Glycan acronym | F-KO #6-10-6 % of total | X-KO #34-4-4 | FX-KO #20-4 |
|---------------|-------------------------|--------------|------------|
| MUX           | 6.8                     |              |            |
| MMX           | 43.1                    |              |            |
| MGnX          | 17.2                    |              |            |
| GnGnX         | 14.5                    |              |            |
| Gn(FA)X       | <1                      |              |            |
| MMF           | 37.5                    |              |            |
| MGnF          | 10.1                    |              |            |
| GnGnF         | 13.5                    |              |            |
| Gn(FA)F       | <1                      |              |            |
| FA/FA         | 2.5                     |              |            |
| MM            | 5.2                     |              |            |
| MGn           | 2.7                     |              |            |
| GnGn          | 2.9                     |              |            |
| Man4          | 3.8                     |              |            |
| Man5          | 4.1                     | 4.8          | 2.2        |
| Man6          | 3.1                     | 4.0          | 3.6        |
| Man7          | 3.7                     | 4.9          | 5.2        |
| Man8          | 4.5                     | 6.2          | 7.1        |
| Man9          | 3.1                     | 4.3          | 4.7        |

### Table 3 LC-ESI-MS analysis of N-glycans released from antibody 2G12 transiently expressed in wild-type N. benthamiana and the F-KO #6-10-6, X-KO #34-4-4 and FX-KO #20-4 lines.

| Glycan acronym | Wild type % of total | F-KO #6-10-6 % of total | X-KO #34-4-4 % of total | FX-KO #20-4 % of total |
|---------------|----------------------|-------------------------|-------------------------|-------------------------|
| Not glyc      | 14.5                 | 14.0                    | 14.0                    | 15.8                    |
| Man7          | 2.0                  | 1.3                     | 2.3                     | 7.8                     |
| Man8          | 5.3                  | 1.3                     | 2.3                     | 7.8                     |
| Man9          | 1.5                  | 3.7                     | 3.7                     | 3.7                     |
| GnM           | 0.5                  | 1.9                     | 2.8                     |                         |
| GnGn          | 1.9                  | 4.7                     | 20.8                    | 65.4                    |
| MMXF          | 1.6                  |                         |                         |                         |
| GnMXF         | 3.4                  |                         |                         |                         |
| GnGnXF        | 62.4                 |                         |                         |                         |
| MMX           | 0.9                  |                         |                         |                         |
| GnUX          | 1.4                  |                         |                         |                         |
| GnMX          | 0.5                  | 7.2                     |                         |                         |
| GnGnX         | 5.0                  | 67.6                    |                         |                         |
| MMF           | 3.0                  |                         |                         |                         |
| GnMF          | 0.3                  | 4.9                     |                         |                         |
| GnGnF         | 1.8                  | 50.3                    |                         |                         |

Symbols: X = β-1,2-xylosylated glycopeptides, F = α-1,3-fucosylated glycopeptides. Percentages describe the relative peak area of the N-glycan as a ratio to the total peak area of the nine (F-KO), 12 (X-KO) or 10 (FX-KO) most common N-glycans. Minor peaks representing the Lewis*-type N-glycan variants were present in all samples, but for F-KO and X-KO the peak area was too small for quantification and thus not included in the calculation. The fucose in Lewis*-type N-glycans (FA) has an α-1,4 linkage and its incorporation is thus not affected by the knockout of the α-1,3-fucosyltransferase genes. Glycan acronyms are based on proglycan nomenclature (http://www.proglycan.com/sites/default/public/pdf/nomen_2007.pdf).

The confirmed knockouts lines F-KO #6-10-6 and X-KO #34-4-4 were crossed to generate a heterozygous FX-KO line. Because N. benthamiana is a self-pollinating plant with delicate flowers, manual crossing is a challenging procedure. To ensure that the progeny of the F-KO #6-10-6 × X-KO #34-4-4 cross were indeed hybrids and not self-pollination products, 20 plants were tested by dot blot with the β-1,2-xylose-specific and α-1,3-fucose-specific antibodies. The plants were expected to have heterozygous mutations in the six XylT and FucT genes and thus show reactivity in both dot blots. To our surprise, we identified FX-KO #20, a line that tested negative in both dot blots (Figure S3a). Sanger sequencing of PCR amplicons showed that one mutated allele per gene was inherited from the parental lines and that new mutations had been induced in the wild-type allele of all six genes (Figure S3b). Antibody 2G12 was transiently expressed in the detached leaves of line FX-KO #20, and the N-glycans of the purified antibody heavy chain were analysed as above (Figure S3c). No β-1,2-xylosylated N-glycans were found, but 11% of the heavy chain glycopeptides contained α-1,3-fucose. N-glycan analysis of the leaf proteome showed that ~50% of N-glycans contained α-1,3-fucose, and that no β-1,2-xylose was present within the limit of detection (Figure S3d, e). This confirmed the complete knockout of the two XylT genes already in the F₁ generation, and a substantial reduction in the level of α-1,3-fucosylation in comparison to wild-type N. benthamiana. The remaining α-1,3-fucosyltransferase activity indicated that some of the newly induced mutations must have been somatic rather than germinal. To investigate the heritability of the mutations, the plant was allowed to self-pollinate and the next generation was analysed.

F₂ generation of candidate line FX-KO #20

Thirty F₂ plants were grown from seeds obtained from the self-pollination of line FX-KO #20 and tested by dot blot analysis with the β-1,2-xylose-specific and α-1,3-fucose-specific antibodies. None of the extracts were recognized by the xylose-specific antibody, and 10 were also not recognized by the fucose-specific
antibody. Selected lines were sequenced, and a plant with putative homozygous or biallelic mutations in all six target genes (Figure 2c) was used for N-glycan analysis, focusing on the transiently expressed antibody 2G12 (Table 3) and the leaf proteome (Table 2, Figure S2c). The total soluble protein of the selected FX-KO and the confirmed F-KO and X-KO lines was tested in Western blots with fucose- and xylose-specific antibodies (Figure 2d). No α-1,3-fucosylated or β-1,2-xylosylated N-glycans were detected, apparently confirming the complete germlinal knockout of all six target genes and the successful generation of the desired \textit{N. benthamiana} FX-KO line.

These results confirm that both \textit{XylT} genes had biallelic germlinal mutations already in the F\textsubscript{1} generation, because otherwise some of the F\textsubscript{2} plants would have inherited wild-type alleles and thus would have been recognized by the xylose-specific antibody. On the other hand, the identification of fucose-positive lines confirms that at least one of the \textit{FucT} genes was not fully mutated in the germline of the F\textsubscript{1} parent plant, and explains the presence of α-1,3-fucosylated N-glycans in that plant.

Functional analysis of antibody glycovariants

To assess the influence of the glycosylation profile on the properties of the recombinant antibody, we conducted a functional binding assay (Figure 3a) based on surface plasmon resonance (SPR) spectroscopy and compared the binding of different 2G12 glycoforms to CD64 (FCGR1A). We used 2G12 produced in Chinese hamster ovary (CHO) cells, in wild-type \textit{N. benthamiana}, and in our FX-KO line, captured equal amounts of purified antibody to a protein A surface, and measured the binding kinetics of eight CD64 dilutions (0.35–44.4 nM). As expected (Sack \textit{et al.}, 2007), the 2G12 produced in wild-type plants showed a much lower affinity for CD64 than the corresponding antibody produced in CHO cells (Figure 3b). However, the affinity of the 2G12 produced in the FX-KO line, lacking plant-specific β-1,2-xylose and core α-1,3-fucose residues, was similar to that of its CHO counterpart (Figure 3b, Figure S5).

Discussion

Ever since scientists became interested in using plants as a production platform for recombinant proteins, there was an awareness that the N-glycans produced in plants could influence the behaviour of pharmaceutical glycoproteins \textit{in vivo} (Parekh \textit{et al.}, 1989). Consequently, there has been a lot of effort to modify the N-glycosylation pathway in a variety of plant species, using T-DNA insertion mutants (Strasser \textit{et al.}, 2004), RNAi (Cox \textit{et al.}, 2006; Sourrouille \textit{et al.}, 2008; Strasser \textit{et al.}, 2008), chemical mutagenesis (Weterings and Van Eldik, 2013) and, more recently, targeted nucleases (Hanania \textit{et al.}, 2017; Li \textit{et al.}, 2016; Mercox \textit{et al.}, 2017). \textit{N. benthamiana} is of particular interest for molecular farming because the transient expression of proteins is fast and yields of more than 2 mg/g fresh leaf weight have been reported for antibodies (Zischewski \textit{et al.}, 2015). \textit{N. benthamiana} is by far the most widely used species in different transient expression platforms, including the MagnICON system (Gleba \textit{et al.}, 2005), the pEAQ vector (Sainsbury \textit{et al.}, 2009), and the pTRA vector (Floss \textit{et al.}, 2008).

Here, we exploited the efficiency and multiplexing capability of the CRISPR/Cas9 system to knockout two β-1,2-xylosyltransferase and four α-1,3-fucosyltransferase genes in \textit{N. benthamiana}. We established several F-KO, X-KO (by multiplexed gene knockout) and FX-KO lines (by crossing F-KO and X-KO), verified the knockout of four (\textit{XylT}), eight (\textit{FucT}) or 12 (\textit{XylT} and \textit{FucT}) targeted alleles at the DNA level, and confirmed—with the detection limit of our assay methods—the absence of each glycosyltransferase activity by analysing both the N-glycans of

Figure 3  CD64 binding behaviour of 2G12 antibody glycovariants as determined by surface plasmon resonance spectroscopy. (a) Assay setup and procedure. Antibody preparations were bound to a protein A surface in previously determined dilutions to result in ~50 response units (RU) of bound antibody after 180 s contact time at a flow rate of 30 μL/min. The relative RU was determined after 10 min of washing with 1x HBS-EP to precisely quantify the amount of antibody bound to the surface. CD64 was injected in one of eight dilutions (44.4–0.35 nM) and the binding kinetics determined by changes in the RU. Not drawn to scale. (b) CD64 binding curves of 2G12 glycovariants produced in wild-type \textit{N. benthamiana}, line FX-KO #20-4 and CHO cells. The curves show the RU changes upon injection of 11.1 nM CD64 dilution (t = 0 to 180 s) and the dissociation of CD64 from the antibody (t = 180 to 780 s). The RU values were corrected for the actual quantities of bound antibody and adjusted to run through the axis origin to improve comparability. The 2G12 expressed in wild-type \textit{N. benthamiana} showed a reduced affinity towards CD64 in comparison to CHO 2G12, but glyco-engineered 2G12 expressed in line FX-KO #20-4 showed a similar affinity and comparable binding behaviour to the CHO version.
total endogenous proteins and the N-glycans of the recombinant antibody 2G12 expressed transiently in the plants. To our knowledge, this is the first report of a complete knockout of FusT and XylT activity in N. benthamiana. We achieved high mutation frequencies in the T₀ generation generated from leaf material infiltrated with the F-KO, X-KO and FX-KO constructs: 73–83% of the T₀ plants were mutated in at least one allele by at least one gRNA. Interestingly, the mutation efficiency of the gRNA targeting the conserved fucosyltransferase motif differed when expressed from the FX-KO and F-KO constructs, and varied from 0%–8% (FX-KO) to 25%–66% (F-KO). Although we anticipated a slightly lower efficiency for this gRNA in FusT 3 and FusT 4 due to the 5′ single-nucleotide mismatch between the target and gRNA sequence (Figure 2b), it was puzzling to see such differences not between gene variants, but between constructs. This phenomenon is unlikely to reflect the dosages of the different gRNAs because the other gRNAs we used performed similarly in both constructs even though there were twice as many gRNAs expressed from the FX-KO construct. One possible explanation for this difference is the position of the gRNA in the polycistronic gRNA-tRNA gene (Figure 1b): in the F-KO construct, this gRNA is in the very last position (4/4) and thus carries a poly(U) tail. In the F-KO construct, it is in the middle position (4/7) and does not have a poly(U) tail, but 1–4 nucleotides of the tRNA leader sequence are present instead (Xie et al., 2015). A similar effect was reported by (Xie et al., 2015) for their gRNA 2: when in position 2/2 in a PTG construct, the gRNA 2 induced biallelic mutations in 76% of plants, but when in position 2/4 only 24% of the plants had biallelic mutations. Taken together, these results suggest that gRNA expressed from the final position of a PTG construct carrying the poly(U) tail is considerably more efficient, but more comprehensive investigations are needed to confirm this.

The much lower mutation efficiency of the “silver bullet” gRNA as expressed from the FX-KO construct—without a single mutation in the FusT 4 gene among 74 T₀ plants—made it impossible to identify a plant with at least monoallelic mutations in all six target genes, even though the overall mutation frequencies were high. One FX-KO line with mutations in both XylT and two of the FusT genes was analysed in the next generation, but the mutations in the FusT genes were not inherited, presumably because they were somatic rather than germline mutations. The occurrence of mosaic or somatic mutations has been observed in N. benthamiana because they were somatic rather than germline mutations. The occurrence of mosaic or somatic mutations has been observed in the T₀ generation of some genome-edited plants (Jia et al., 2016; Nekrasov et al., 2013; Wang et al., 2015), which is why it is necessary to follow their inheritance through to the following generation. Indeed, we also observed the appearance of both somatic and germline mutations in the hybrid F₁ generation due to sustained Cas9 activity in the transgenic lines.

The N. benthamiana genome contains five α-1,3-fucosyltransferase genes, but our results show that the FusT 5 gene lacking a TATA box, intron and key catalytic motif does not need to be knocked out to prevent the synthesis of α-1,3-fucosylated N-glycans. These data indicate that FusT 5 is likely to be an inactive pseudogene. Furthermore, we found that in plants with biallelic or homozygous mutations in FusT 1, 3 and 4, one intact allele of the FusT 2 gene is not sufficient to compensate for the FusT-deficient phenotype. In dot blots probed with an α-1,3-fucose-specific antibody, we did not observe any clear difference in signal intensity between the aforementioned plant lines with one intact FusT 2 allele and plants mutated in all eight alleles of the four FusT genes (Figure S1d, F-KO #35-8 vs. #35-8-13). This indicates that the FusT 2 gene—which is classed as a pseudogene in the NCBI GenBank database (accession number EF 562631)—contributes little or nothing to the overall α-1,3-fucosyltransferase activity in N. benthamiana, at least in leaves and under the experimental conditions we examined.

When analysing the endogenous N-glycan composition of the F-KO, X-KO and FX-KO lines, we observed similar ratios of complex or paucimannosidic (~75%–80%) to high-mannose (~20%–25%) N-glycans for the three lines (Table 2). The main glycoform in the FX-KO line was GnGn in contrast to MMF in X-KO and MMX in F-KO. This difference can be explained with the findings of a recent study (Shin et al., 2017), which showed that the trimming of terminal GlcNAc residues in GntGn(X/F) glycoforms by a specific β-hexosaminidase is promoted by the presence of either β-1,2-xyllose or α-1,3-fucose. The absence of these sugar residues from the endogenous N-glycans of the FX-KO line thus results in less trimming and consequently a higher content of GntGn. For the 2G12 glycovariants, on the other hand, the main glycoforms were GntGn(FX) variants in all tested samples (Table 3) as was the case for the 2G12 glycovariants expressed in the RNAi N. benthamiana lines by Strasser et al. (2008), likely because the antibody heavy chain is not a substrate for the β-hexosaminidases present in the cell (Shin et al., 2017).

The F-KO, X-KO and FX-KO lines we generated were devoid of β-1,2-xyllose and/or α-1,3-fucose, the CRISPR-induced mutations from T₁ onwards were inherited by progeny plants, and the plants grew normally and expressed 2G12 at comparable levels following agroinfiltration (not shown). Together, the glyco-engineered F-KO, X-KO and FX-KO N. benthamiana lines offer considerable flexibility for the expression of glycoproteins in plants and will allow the effects of β-1,2-xyllosylation and α-1,3-fucosylation on recombinant proteins to be studied in great detail, as shown for the 2G12 antibody. Furthermore, the lines can be used as a starting point for additional glyco-engineering to reproduce human N-glycosylation patterns, such as the introduction of pathways for the production, activation, transport and transfer of sialic acid to terminal galactose residues (Castilho et al., 2010).

From a plant physiology standpoint, it is also interesting to note that none of the three N. benthamiana knockout lines exhibited an obvious phenotype under greenhouse conditions, as also reported for A. thaliana triple mutants (Strasser et al., 2004). This suggests that the presence of the plant-specific xylose and core-fucoside residues is not essential for survival, development or reproduction in N. benthamiana. Possibly, they are relevant in the context of biotic or abiotic stress, but further investigation is required to test this hypothesis.

We did not investigate off-target effects because this was beyond the scope of our work, but the absence of an obvious phenotype indicates that no major unwanted genomic changes have occurred. To ensure genome stability in later generations, we designed the knockout constructs in such a way that allows their excision using CRISPR/Cas9 or the Cre/loxP system in case T-DNA segregation is desired but not possible.

In conclusion, we have demonstrated that the highly efficient CRISPR/Cas9 system allows the rapid generation of N. benthamiana plants in which two, four or six endogenous genes are knocked out. We confirmed the inheritance of the induced mutations up to the T₃ (F-KO and X-KO) and F₃ (FX-KO, see Figure S4) generations, as well as the intended xylose/core-fucose-free phenotypes by N-glycan analysis. Finally, we showed that an antibody produced in the FX-KO line displays higher affinity CD64 receptor binding than the same antibody produced.

© 2018 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 17, 350–361
in wild-type plants, and comparable affinity to the gold standard produced in CHO cells. This highlights the importance of our knockout lines for the production of efficacious biopharmaceutical glycoproteins.

Experimental procedures
Resequencing the target genes and gRNA design
Genomic DNA was extracted from wild-type *N. benthamiana* Rdr1 insertion genotype (Bally et al., 2015; Spiegel et al., 2015) leaf material using the NucleoSpin Plant II kit (Macherey-Nagel, Düren, Germany). Potential target regions of the selected genes XylT 1, XylT 2, FucT 1, FucT 2, FucT 3, FucT 4 and FucT 5 were amplified from genomic DNA using the Expand High Fidelity PCR system (Roche, Basel, Switzerland), purified from agarose gels using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel) and sequenced using the Sanger method prior to gRNA design, with the primers listed in Table S1. All primers were purchased from Eurofins Genomics (Ebersberg, Germany). The sequences were aligned in three groups (XylT 1 and 2; FucT 1 and 2; FucT 3, 4 and 5) and the gRNAs were designed to target all genes in a group. CRISPR-P v1.0 (Lei et al., 2014) was used to assess the potential off-target sites of each gRNA. We set the allowed maximum off-target score to 5 of 100 possible points, and excluded gRNAs whose 12-nt seed region had a perfect match in a coding sequence elsewhere in the genome. In addition, all gRNA candidates were used as BLAST queries against the *N. benthamiana* genome scaffold v0.5 (http://bentgenome.qut.edu.au/) to identify further potential off-targets.

Cloning of CRISPR constructs for gRNA testing and stable transformation
The 12 gRNAs selected to be tested by transient expression were obtained as String DNA Fragments (Thermo Fisher Scientific/Oxford ClonTech, CA, USA) and with the seven gRNAs combined (FX-KO). The three knockout constructs were based on targeting *cas9* genes 2 and 3, one with the seven gRNAs 4 and 5) and the gRNAs were designed to target all genes in a group. CRISPR-P v1.0 (Lei et al., 2014) was used to assess the potential off-target sites of each gRNA. We set the allowed maximum off-target score to 5 of 100 possible points, and excluded gRNAs whose 12-nt seed region had a perfect match in a coding sequence elsewhere in the genome. In addition, all gRNA candidates were used as BLAST queries against the *N. benthamiana* genome scaffold v0.5 (http://bentgenome.qut.edu.au/) to identify further potential off-targets.

**Stable transformation and plant cultivation**
Agroinfiltrated *N. benthamiana* leaves were harvested after 4–5 days, surface sterilized, rinsed three times with sterile water, cut into ~2-cm² pieces and placed on shooting medium selection plates (MS II: MS medium, 1 mg/L 6-benzylaminopurine, 0.1 mg/L naphthaleneacetic acid, 100 mg/L kanamycin, 200 mg/L cefotaxime, pH 5.8) and kept under controlled conditions (25 °C, 16-h photoperiod). After 3–4 weeks, shoots appeared, were cut, transferred to MS III plates (MS medium, 100 mg/L kanamycin, 200 mg/L cefotaxime, pH 5.8) and incubated at 23–25 °C until roots formed after 10–14 days. The plantlets were then transferred into Weck jars containing MS III medium, incubated for 2 weeks and then transferred to soil.

**Extraction of genomic DNA**
For next-generation sequencing, high-quality genomic DNA was extracted from infiltrated leaf material using the NucleoSpin Plant II kit. For direct sequencing and HRMA, genomic DNA was extracted using the alkaline lysis method (Xin et al., 2003). Briefly, a leaf disc with a diameter of ~3 mm was placed in 50 μL of buffer A (100 mM NaOH, 2% Tween-20) and incubated at 95 °C for 10 min before adding 50 μL of buffer B (100 mM Tris-HCl, 2 mM EDTA, pH 2.0) to adjust the pH. We then used 0.5–1 μL of the crude extract as a template for PCR or 0.25 μL as a template for HRMA in 20-μL reaction mixes. The extracts were stored at 4 °C.

**Amplification of target regions and Sanger sequencing of amplicons**
The gRNA target regions were amplified from 1 μL of genomic DNA extract using Q5 Hot Start High-Fidelity 2X Master Mix (New England Biolabs) in a 20-μL reaction, and the products purified either directly or from agarose gels using the NucleoSpin Gel and PCR Clean-up kit, or by robot-assisted PCR clean-up with NucleoFast 96 PCR plates (Macherey-Nagel). The amplicons were then sequenced in house using the Sanger method, and the results were analysed using Clone Manager v9 Professional (Scientific & Educational Software, Denver) and the online tool TIDE (Brinkman et al., 2014). When the sequencing results were ambiguous, the PCR products were cloned in pTOPO from the TOPO TA Cloning Kit (Thermo Fisher Scientific, Waltham) and 5–10 clones were sequenced individually for each sample. A detailed explanation of the analysis procedure can be found in Appendix S2 and Figure S6.
High-resolution melt analysis

For the initial screening of T1 generation plants, the targeted regions were amplified from 0.25 μl genomic DNA extract using IQ Sybr Green Supermix (Bio-Rad, Munich, Germany) in a 20-μl reaction volume (10 μl 2 x Supermix, 0.5 μm forward primer, 0.5 μm reverse primer, 0.25 μl genomic DNA, 6 μl deionized water) in a LightCycler 480 Real-Time PCR system (Roche Molecular Diagnostics, Pleasanton, CA) for 2 h in standard TBS-T (anti-xylose, 1:5000) incubated with a 1:10 000 dilution of the secondary antibody (Jackson ImmunoResearch Laboratories, West Grove) pre-absorbed to remove antibodies binding unspecifically to plant leaf extract. For this purpose, two gel lanes were loaded with a high concentration of wild-type N. benthamiana leaf extract, blotted, blocked, and then incubated with a 1:10 000 dilution of the secondary antibody in standard TBS-T. After 1.5–2 h of pre-absorption, the antibody dilution was collected, the membrane briefly rinsed with high-salt TBS-T, and both fractions pooled to obtain a medium-salt antibody solution.

After incubation with the primary antibody, the sample membranes were washed 3x in the standard (anti-xylose) or high-salt (anti-fucose) TBS-T, and then incubated with the pre-absorbed secondary antibody for 1 h. The membranes were washed 3x in high-salt TBS-T and 1x in AP buffer, and then developed by adding 100 μl BCIP/NBT in 10 ml AP buffer and incubation in the dark at RT.

Glycoprotein purification and analysis

The infiltrated frozen leaf material was weighed and extracted in 2–3 volumes of protein extraction buffer as described above using a mortar and pestle. The homogenate was filtered through Miracloth (Merck, Darmstadt, Germany), adjusted to pH 7.4 with 0.1 volumes of 1 M Tris (pH 8.0), and then centrifuged at 3220 g at 4 °C for 20 min. Protein A columns for affinity chromatography were prepared by pipetting 0.5 μl of Protein A Ceramic HyperF ( Pall, Dreieich, Germany) into a column and equilibrating with 10 column volumes of PBS. After loading the supernatant and washing with 10 column volumes of PBS, the bound antibodies were eluted in an elution buffer suitable for 2G12 (100 mM glycine, 100 mM fructose, pH 3.6). Seven eluate fractions of 500 μl were captured and buffered with 0.1 volumes of 1 M acetate buffer (pH 4.75). The protein content of the eluate was quantified using a NanoDrop ND1000 spectrophotometer (Thermo Fisher Scientific) and the fraction with the highest concentration was used for CD64 receptor binding assays. The samples were mixed with 4x NuPAGE Sample Buffer, 10x NuPAGE Reducing Agent (Thermo Fisher Scientific) and incubated at 70 °C for 10 min. The samples were separated by SDS-PAGE at 200V for 35 min using precast NuPAGE Novex 4%–12% Bis-Tris protein gels and NuPAGE MES SDS Running Buffer (Thermo Fisher Scientific). After staining with Coomassie Brilliant Blue (Fairbanks et al., 1971; Wong et al., 2000), the antibody heavy chain bands from four lanes loaded with the same sample were pooled for N-glycan analysis (Appendix S3) as previously described (Kolarich and Altmann, 2000; Strasser et al., 2008). Figure S5b shows the Coomassie-stained gels of the 2G12 glycovariants.

N-glycan analysis of total endogenous leaf proteins

Several young leaves (0.5–1 g) from different parts of the plant were harvested and N-glycans of endogenous proteins released by PNGase A were analysed by MALDI-TOF mass spectrometry as previously described (Strasser et al., 2004, 2008).

Comparison of antibody glycovariant binding kinetics to CD64 (FGCR1A) by surface plasmon resonance spectroscopy

Protein A-purified antibody preparations (2G12 WT, 2G12 FX-KO) and human monoclonal antibody 2G12 (Polymun Scientific, Klosterneuburg, Austria) were diluted in HPS-EP buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% Tween-20, pH 7.4) for pre-quantification on a protein A surface by surface plasmon resonance spectroscopy using Biacore T200 instrument (GE Healthcare, Freiburg, Germany). Based on the resulting response units (RU), the antibody samples were then diluted to yield 50 RU after 180 s contact with a 30 μl/s flow rate on the protein A surface. The lyophilized CD64 (FCGR1A) receptor (Sino Biological, Beijing, China) was reconstituted in water and serially diluted to 0.35, 0.7, 1.4, 2.8, 5.6, 11.1, 22.2 and 44.4 RU. To determine the binding kinetics between the antibody variants and CD64, ~50 RU of the antibody were bound to the protein A surface, and increasing concentrations of the receptor were injected with 180 s contact time, followed by 10 min dissociation. The resulting binding curves were analysed using the BIA evaluation software. The curves shown here were derived from the original spectrograms, corrected with the actual RU value (corrected RU = raw RU− RU antigen*(50 RUantibody/actual RUantibody), and normalized to start at the axis origin (x = 0/y = 0).

Acknowledgements

This work was partly supported by the ERC Advanced Grant Future-Pharma (269110) and by the Excellence Initiative of the German federal and state governments. The authors would like to acknowledge the help of the following colleagues: Flora Schuster (plant tissue culture), Ibrahim Al Amedi (greenhouse), Leonie Fritsch (NGS), Alexander Boes (protein purification), Claudia Hansen and Raphael Soeur (robot-assisted PCR clean-up, sequencing), Thomas Rademacher (2G12 construct). HBT-pco-Cas9 was a gift from Jen Sheen (Addgene plasmid #52254). We
thank Friedrich Altmann and Clemens Gruenwald-Gruber (BOKU Vienna) for the N-glycan analysis and Richard M. Twyman for editing the manuscript. The authors declare no conflict of interest.

References

Alonso, J.M., Stepanova, A.N., Leisse, T.J., Kim, C.J., Chen, H., Shinn, P., Stevenson, D.K. et al. (2003) Genome-wide insertional mutagenesis of Arabidopsis thaliana. Science, 301, 653–657.

Bally, J., Nakagaki, K., Ito, F., Jung, H., Ho, S.Y.W., Wong, M., Paul, C.M. et al. (2015) The extremophile Nicotiana benthamiana has traded viral defence for early vigour. Nature Plants, 1, 15165.

Bardor, M., Faveau, C., Frichtet, A.-C., Gilbert, D., Galas, L., Trottein, F., Fayé, L. et al. (2003) Immunoreactivity in mammals of two typical plant glycoepitopes, core α(1,3)-fucosyl and core xlose. Glyobiology, 13, 427–434.

Bomarely, A., Rosli, H.G., Vrebaval, J., Moffett, P., Mueller, L.A. and Martin, G.B. (2012) A draft genome sequence of Nicotiana benthamiana to enhance molecular plant-microbe biology research. Mol. Plant Microbe Interact. 25, 1523–1530.

Brinkman, E.K., Chen, T., Amendola, M. and van Steensel, B. (2014) Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168.

Castillo, A., Strasser, R., Stadlmann, J., Grass, J., Jez, J., Gattinger, P., Kunert, R. et al. (2010) In planta protein sialylation through overexpression of the respective mammalian pathway. J. Biol. Chem. 285, 15923–15930.

Castillo, A., Bohorova, N., Grass, J., Bohorov, O., Zeitlin, L., Whaley, K., Alltmann, F. et al. (2011) Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody. PLoS One, 6, e26040.

Cho, S.W., Kim, S., Kim, Y., Kweon, J., Kim, H.S., Bae, S. and Kim, J.S. (2014) Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 24, 132–141.

Christian, M., Cermak, T., Doyle, E.L., Schmidt, C., Zhang, F., Hummel, A., Bogdanove, A.J. et al. (2010) Targeting DNA double-strand breaks with TAL effector nucleases. Genetics, 186, 757–761.

Cox, K.M., Sterling, J.D., Regan, J.T., Gasadaska, J.R., Frantz, K.K., Pege, C.G., Black, A. et al. (2006) Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat. Biotechnol. 24, 1591–1597.

Dent, M., Hurtado, J., Paul, A.M., Sun, H., Lai, H., Yang, M., Esqueda, A. et al. (2016) Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity. J. Gen. Virol. 97, 3280–3289.

Dwight, Z.L., Palais, R. and Wittwer, C.T. (2012) uAnalyze: web-based high-resolution DNA melting analysis with comparison to thermodynamic predictions. IEEE/ACM Trans. Comput. Biol. Bioinf. 9, 1805–1811.

Fairbanks, G., Steck, T.L. and Wallach, D. (1971) Electrophoretic analysis of the enzyme replacement therapy using plant cell expression technology. Mol. Genet. Metab. 112, 1–8.

Hall, G., Allen, G.C., Loer, D.S., Thompson, W.F. and Spiker, S. (1991) Nuclear scaffolds and scaffold-attachment regions in higher plants. Proc. Natl. Acad. Sci. 88, 9320–9324.

Hanania, U., Ariel, T., Tekoah, Y., Fux, L., Sheva, M., Gubbay, Y., Weiss, M. et al. (2017) Establishment of a tobacco BY2 cell line devoid of plant specific xylose and fucose as a platform for the production of therapeutically relevant proteins. Plant Biotechnol. J. 15, 1120–1129.

Hatt, A., CaFFerkey, R. and Bowdish, K. (1989) Production of antibodies in transgenic plants. Nature, 342, 76–78.

Huehner, C.M., Lienhart, O., Baur, A., Stemmer, C., Gorr, G., Reski, R. and Decker, E.L. (2005) Glyco-engineering of moss lacking plant-specific sugar residues. Plant Biology (Stuttgart), 7, 292–299.

Jia, H., Orbovic, V., Jones, J.B. and Wang, N. (2016) Modification of the PIIIa effector binding elements in Type I Cas9 DNA rupture promoter using Cas9/sil4RNA to produce transgenic Duncan grapefruit alleviating XccAmpAA35CLO13 infection. Plant Biotechnol. J. 14, 1291–1301.

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A. and Charpentier, E. (2012) A programmable dual RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337, 816–821.

Jost, F., de Vries, T., Knetig, R.M.A. and Machamer, B.A. (2005) Mutation of amino acids in the alpha 1,3-fucosyltransferase motif affects enzyme activity and Km for donor and acceptor substrates. Glycobiology, 15, 165–175.

Kim, Y.G., Cha, J. and Chandrasegaran, S. (1996) Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. 93, 1156–1160.

Ko, K., Tekoah, Y., Rudd, P.M., Harvey, D.J., Dwek, R.A., Spitsin, S., Hanlon, C.A. et al. (2003) Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc. Natl. Acad. Sci. 100, 8013–8018.

Kolarich, D. and Alltmann, F. (2000) N-Glycan analysis by matrix-assisted laser desorption/ionization mass spectrometry of electrophoretically separated nonmammalian proteins: application to peanut allergen Ara h 1 and Olive Pollen Allergen Ole e 1. Anal. Biochem. 285, 64–75.

Lei, Y., Lu, L., Liu, H.-Y., Li, S., Xing, F. and Chen, L.-L. (2014) CRISPR-P: a web tool for synthetic single-guide RNA design of CRISPR-system in plants. Molecular Plant, 7, 1494–1496.

Lerouge, P., Cabanes-Macheteau, M., Rayon, C., Fischette-Lainé, A.-C., Gomord, V. and Faye, L. (1998) N-Glycoprotein biosynthesis in plants: recent developments and future trends. Plant Mol. Biol. 38, 31–48.

Li, J.-F., Norville, J.E., Aach, J., McCormack, M., Zhang, D., Bush, J., Church, G.M. et al. (2013) Multiplex and homologous recombination-mediated genome editing in Arabidopsis and Nicotiana benthamiana using guide RNA and Cas9. Nat. Biotechnol. 31, 688–691.

Li, J., Stoddard, T.J., Demorest, Z.L., Lavoie, P.O., Luo, S., Clasen, B.M., Cerdron, F. et al. (2016) Multiplexed, targeted gene editing in Nicotiana benthamiana for glyco-engineering and monoclonal antibody production. Plant Biotechnol. J. 14, 533–542.

Loos, A. and Steinkellner, H. (2014) Plant glyco-biotechnology on the way to synthetic biology. Frontiers Plant Sci. 5, 523.

Loos, A., Gach, J.S., Hackl, T., Maresch, D., Henkel, T., Porodko, A., Bui-Minh, D. et al. (2015) Glycan modulation and sulfonation engineering of anti-HIV-1 monoclonal antibody PG9 in plants. Proc. Natl. Acad. Sci. 112, 12675–12680.

Merck, S., Smargiasso, N., Chaumont, F., De Pauw, E., Boutry, M. and Navarre, C. (2017) Inactivation of the (1,2)-xylosyltransferase and the α(1,3)-fucosyltransferase genes in Nicotiana tabacum BY-2 cells by a multiplex CRISPR/Cas9 strategy results in glycoproteins without plant-specific glycans. Frontiers Plant Sci. 8, 403.

Mor, T.S. (2015) Molecular pharming's foot in the FDA's door: Protalix's BetaThaloz for thalassemia major. Plant Biotechnol. J. 112, 379–391.

Gleba, Y., Klimyk, V. and Maillonnement, S. (2005) Magnification—a new platform for expressing recombinant vaccines in plants. Vaccine, 23, 2042–2048.

Gomord, V., Fichette, A.-C., Menu-Bouaouche, L., Saint-Jore-Dupas, C., Plisson, C., Michaud, D. and Faye, L. (2010) Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotechnol. J. 8, 564–587.

Grabowski, G.A., Golembo, M. and Shaaltiel, Y. (2014) Taliglucerase alfalfa: an enzyme replacement therapy using plant cell expression technology. Mol. Genet. Metab. 112, 1–8.

Hall, G., Allen, G.C., Loer, D.S., Thompson, W.F. and Spiker, S. (1991) Nuclear scaffolds and scaffold-attachment regions in higher plants. Proc. Natl. Acad. Sci. 88, 9320–9324.
Sourrouille, C., Marquet-Blouin, E., D’Aoust, M.-A., Kiefer-Meyer, M.-C., Seveno, Strasser, R., Stadlmann, J., Sch tekoah, Y., Tzaban, S., Kizhner, T., Hainrichson, M., Gantman, A., Golembo, M., Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N., Sch Santos, R.B., Abranches, R., Fischer, R., Sack, M. and Holland, T. (2016) Putting Shaaltiel, Y. and Tekoah, Y. (2016) Plant specific N-glycans do not have proven Sack, M., Hofbauer, A., Fischer, R. and Stoger, E. (2015) The increasing value of €
Strasser, R., Altmann, F., Mach, L., Gl ossl, J. and Steinkellner, H. (2004) Down-regulated expression of plant-specific glycopeptidases in alfalfa. Plant Biotechnol. J. 6, 702–721. Spiegel, H., Boes, A., Voelpel, N., Beiss, V., Edgue, G., Rademacher, T., Sack, M. et al. (2015) Application of a scalable plant transient gene expression platform for malaria vaccine development. Frontiers Plant Sci. 6, 1169. Stemberg, N. and Hamilton, D. (1981) Bacteriophage P1 site-specific recombination. J. Mol. Biol. 150, 467–486. Strasser, R., Altmann, F., Mach, L., Gl osl, J. and Steinkellner, H. (2004) Generation of Arabidopsis thaliana plants with complex N-glycans lacking J1,2-linked xylose and core α1,3-linked fucose. FEBS Lett. 561, 132–136. Strasser, R., Stadlmann, J., Schäus, M., Steiger, G., Quendler, H., Mach, L., Gl osl, J. et al. (2008) Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 6, 392–402. Tekoah, Y., Tzaban, S., Kühner, T., Hainrichson, M., Gantman, A., Golembo, M., Aviezer, D. et al. (2013) Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems. Biosci. Rep. 33, e00071. Tekoah, Y., Shulman, A., Kühner, T., Ruderfer, I., Fox, L., Nataf, Y., Bartfeld, D. et al. (2015) Large-scale production of pharmaceutical proteins in plant cell culture—the protaxil experience. Plant Biotechnol. J. 13, 1199–1208. Trkola, A., Purtshcer, M., Mustet, T., Ballaun, C., Buchacher, A., Sullivan, N., Sirivasan, K. et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100–1108.

Wang, Z.P., Xing, H.L., Dong, L., Zhang, H.Y., Han, C.Y., Wang, X.C. and Chen, Q.J. (2015) Egg cell-specific promoter-controlled CRISPR/Cas9 efficiently generates homozygous mutants for multiple target genes in Arabidopsis in a single generation. Genome Biol. 16, 144. Ward, B.J., Landry, N., Trépanier, S., Mercier, G., Dargis, M., Couture, M., D’Aoust, M.-A. et al. (2014) Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine, 32, 6098–6106. Weterings, K. and Van Eldik, G. (2013) Nicotiana benthamiana plants deficient in fucosyltransferase activity. International patent application WO 2013/ 050155. Wong, C., Sridhara, S., Bardwell, J.C. and Jakob, U. (2000) Heating greatly speeds Coomassie blue staining and destaining. Biotechniques, 28, 426–428, 430, 432. Xie, K., Minkenberg, B. and Yang, Y. (2015) Boosting CRISPR/Cas9 multiplex editing capability with the endogenous tRNA-processing system. Proc. Natl. Acad. Sci. 112, 3570–3575. Xin, Z., Velten, J.P., Oliver, M.J. and Burke, J.J. (2003) High-throughput DNA extraction method suitable for PCR. Biotechniques, 34, 820–827. Zelkin, L., Pettitt, J., Scully, C., Bohorava, N., Kim, D., Pauly, M., Hutt, A. et al. (2011) Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. 108, 20690–20694. Zetsche, B., Gootenberg, J.S., Abudayyeh, O.O., Slaymaker, I.M., Makarova, K.S., Esletzbichler, P., Volz, S.E. et al. (2015) Cpf1 Is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell, 163, 759–771. Zischewski, J., Sack, M. and Fischer, R. (2015) Overcoming low yields of plant-made antibodies by a protein engineering approach. Biotechnol. J. 11, 107–116.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1 Dot blots for T1 and T2 X-KO and F-KO plants.
Figure S2 Leaf proteome N-glycan analysis for F-KO #6-10-6, X-KO #34-4-4 and FX-KO #20-4.
Figure S3 Analysis of the hybrid F1 generation line FX-KO #20.
Figure S4 Dot blots of 50 F3 progeny plants of FX-KO #20-4.
Figure S5 SPR assay for CD64 binding of 2G12 glycovariants.
Figure S6 Examples for Sanger sequencing chromatograms.
Table S1 Primers for the amplification and sequencing of genomic target regions.
Table S2 Primers for the preparation of NGS samples.
Table S3 Mutations frequencies of gRNAs in transient.
Table S4 Mutations in selected F-KO and X-KO T0 lines.
Table S5 Primers for HRMA analysis.
Table S6 Mutations in selected F-KO T1 plants.
Appendix S1 Next-generation sequencing.
Appendix S2 Sanger sequencing chromatogram analysis.
Appendix S3 Antibody N-glycan analysis by LC-ESI-MS.
Appendix S4 Dot blots of knockout candidate lines.